NCT06452433View on ClinicalTrials.gov

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 12, 2027

Study Completion Date

February 2, 2028

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

gumarontinib

300 mg , qd ,po, expect 6 months.

DRUG

third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)

According to the actual situation of patients. Take as recommended, expect 6 months.

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06452433 - Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. | Biotech Hunter | Biotech Hunter